Format

Send to

Choose Destination
Hematol Oncol Clin North Am. 2011 Oct;25(5):981-95, v. doi: 10.1016/j.hoc.2011.09.004. Epub 2011 Oct 19.

Chronic myeloid leukemia: mechanisms of resistance and treatment.

Author information

1
The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ejabbour@mdanderson.org

Abstract

Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

PMID:
22054730
PMCID:
PMC4428141
DOI:
10.1016/j.hoc.2011.09.004
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center